Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07229417 · ClinicalTrials.gov registry record · Phase 2
IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
A Phase 2 study of Metastatic Endocrine Refractory and Triple Negative Invasive Lobular Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT07229417 is a Phase 2 study of Metastatic Endocrine Refractory and Triple Negative Invasive Lobular Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07229417, a Phase 2 study of Metastatic Endocrine Refractory and Triple Negative Invasive Lobular Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.
Conditions Studied
Interventions
- DRUG Ivonescimab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07229417
The ClinicalTrials.gov registry entry for NCT07229417 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Endocrine Refractory appearing as the primary indexed condition, and to 1 intervention - of which Ivonescimab is the first listed.
NCT07229417 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07229417 about?
NCT07229417 is a clinical study titled "IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma". To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.
What is the current status of trial NCT07229417?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2025-10-22. Estimated completion is 2029-09-30.
What conditions does trial NCT07229417 study?
This clinical trial studies the following conditions: Metastatic Endocrine Refractory, Triple Negative Invasive Lobular Carcinoma.
What interventions are being tested in trial NCT07229417?
The interventions under investigation include: Ivonescimab (DRUG).
Who is sponsoring clinical trial NCT07229417?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07229417 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Metastatic Endocrine Refractory
All registered trials for this condition
Triple Negative Invasive Lobular Carcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.